Results 101 to 110 of about 2,831 (235)
BMC Ophthalmology, 2021 Background To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). Methods A retrospective, observational study.
Xin Nie +3 more
doaj +1 more source
Frontiers in Physiology, 2022 PurposeTo investigate the influence of preoperative adjunctive anti-VEGF drug (Conbercept) on vitreous inflammatory cytokines and chemokines profiles and whether those cytokines were associated with early macular edema (ME) after surgery for patients ...
Hongyan Sun +13 more
doaj +1 more source
Recent Advancements in the Treatment of Age‐Related Macular Degeneration
Med Research, Volume 1, Issue 2, Page 151-169, September 2025.ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu +10 more
wiley +1 more source
Clinical Interventions in Aging, 2017 Chunmei Cui, Hong Lu Department of Ophthalmology, Beijing Chao-Yang Hospital, Beijing, China Purpose: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of age-related macular degeneration (AMD). Although
Cui C, Lu H
doaj
Real-world outcomes of two-year Conbercept therapy for diabetic macular edema
International Journal of Ophthalmology, 2021 AIM: To evaluate the two-year outcomes of patients treated for diabetic macular edema (DME) with intravitreal Conbercept (IVC). METHODS: The clinical data of 30 DME patients (36 eyes) were retrospectively reviewed. The patients were treated with IVC for 3mo. Additional IVC was given at subsequent monthly visits, if needed (3+PRN).
Yong Cheng +3 more
openaire +3 more sources
iMetaOmics, Volume 2, Issue 2, June 2025.This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang +7 more
wiley +1 more source
Anti-vascular endothelial growth factor therapies in ophthalmology [PDF]
Background: Retinal diseases, including neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, are leading causes of vision loss worldwide.
Karti, Omer +2 more
core +2 more sources
A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
Scientific Reports, 2018 AbstractIntravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations.
Yong Cheng +4 more
openaire +3 more sources
Natural products targeting tumour angiogenesis
British Journal of Pharmacology, Volume 182, Issue 10, Page 2094-2136, May 2025.Abstract Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti‐angiogenic properties and can be used to inhibit tumour ...
Xiaohua Lu +2 more
wiley +1 more source
VEGFR1 signaling in retinal angiogenesis and microinflammation [PDF]
, 2021 Five vascular endothelial growth factor receptor (VEGFR) ligands (VEGF-A, -B, –C, -D, and placental growth factor [PlGF]) constitute the VEGF family. VEGF-A binds to VEGF receptors 1 and 2 (VEGFR1/2), whereas VEGF-B and PlGF only bind VEGFR1.
Brunck, LR +10 more
core